# Parkinson Disease: Diagnosis and Early Management

## Overview

Parkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease, with prevalence increasing with age and affecting approximately 1% of the population over 60. The pathological hallmark is loss of dopaminergic neurons in the substantia nigra pars compacta accompanied by Lewy body inclusions composed of aggregated alpha-synuclein. The disease extends far beyond dopamine, affecting multiple neurotransmitter systems including norepinephrine, serotonin, and acetylcholine, which explains the wide range of non-motor symptoms that accompany and often precede the motor features.

## Cardinal Motor Features

### Bradykinesia

Bradykinesia is the hallmark feature and is required for diagnosis. It manifests as a progressive reduction in both speed and amplitude of repetitive movements, characterized by a decrement pattern. It is tested clinically through finger tapping, hand opening and closing, pronation-supination, and toe tapping. Bradykinesia must be distinguished from the pyramidal slowness of upper motor neuron lesions or the deliberate slowness seen in depression.

### Resting Tremor

The classic PD tremor is a 4-6 Hz "pill-rolling" tremor present at rest. It suppresses with voluntary movement but may re-emerge when maintaining a posture (re-emergent tremor). Approximately 70% of patients have resting tremor at diagnosis. Unilateral onset is characteristic, and the tremor remains asymmetric throughout the disease course.

### Rigidity

Rigidity in PD presents as "lead-pipe" resistance that is uniform throughout the range of motion. When tremor is superimposed on lead-pipe rigidity, the result is "cogwheel" rigidity. Rigidity can be enhanced by having the patient perform voluntary movements with the contralateral limb (the Froment maneuver).

### Postural Instability

Postural instability is typically a later feature of PD; its early presence should raise suspicion for atypical parkinsonism such as progressive supranuclear palsy. It is assessed clinically using the pull test, which evaluates the retropulsive response.

## Diagnostic Criteria

### MDS Clinical Diagnostic Criteria (2015)

The essential criterion for parkinsonism is bradykinesia combined with at least one of resting tremor or rigidity. Supportive criteria for PD include a clear beneficial response to dopaminergic therapy, the presence of levodopa-induced dyskinesia, and rest tremor of a limb. Absolute exclusion criteria include cerebellar abnormalities, downward vertical supranuclear gaze palsy, behavioral variant frontotemporal dementia or primary progressive aphasia within 5 years, parkinsonian features restricted to the lower limbs for more than 3 years, treatment with a dopamine receptor blocking agent at a dose and time-course consistent with drug-induced parkinsonism, absence of observable response to high-dose levodopa, unequivocal cortical sensory loss or clear limb apraxia or progressive aphasia. Red flags that suggest an alternative diagnosis include rapid progression, early bulbar dysfunction, severe autonomic failure within 5 years, early recurrent falls, disproportionate anterocollis, absence of common non-motor features after 5 years, pyramidal tract signs, and bilateral symmetric parkinsonism throughout.

### Clinically Established vs. Clinically Probable PD

Clinically established PD requires no absolute exclusion criteria, no red flags, and at least 2 supportive criteria. Clinically probable PD requires no absolute exclusion criteria, with any red flags counterbalanced by supportive criteria.

<image>Diagram illustrating the MDS clinical diagnostic criteria algorithm for Parkinson disease with supportive criteria, red flags, and exclusion criteria</image>

## Role of Neuroimaging

### DaTscan (Ioflupane I-123 SPECT)

DaTscan images the dopamine transporter in the striatum and shows reduced uptake in the posterior putamen in PD. It is useful for distinguishing PD from essential tremor, drug-induced parkinsonism, psychogenic tremor, and dystonic tremor. However, it cannot distinguish PD from atypical parkinsonism (MSA, PSP, CBD), as all of these conditions show reduced DAT uptake.

### MRI Brain

Standard MRI is typically normal in PD, making it primarily useful for excluding structural causes of parkinsonism. At 3T or 7T, loss of the nigrosome-1 signal on susceptibility-weighted imaging (the absent "swallow tail" sign) correlates with nigral degeneration.

### Emerging Biomarkers

Alpha-synuclein seed amplification assays (SAA) in CSF and skin biopsy represent a paradigm shift toward a biological definition of PD. The 2023 Neuronal Synuclein Disease Integrated Staging System (NSD-ISS) has proposed biological staging of the disease based on these markers.

<image>DaTscan images comparing normal dopamine transporter uptake with the asymmetric posterior putaminal loss seen in early Parkinson disease</image>

## Non-Motor Symptoms

Non-motor symptoms often precede motor symptoms by years to decades, defining what is now recognized as prodromal PD. Anosmia is present in more than 90% of PD patients and can be tested with the UPSIT (University of Pennsylvania Smell Identification Test). REM sleep behavior disorder is a powerful predictor of future alpha-synucleinopathy, with more than 80% of patients phenoconverting at 15 years. Constipation reflects enteric nervous system alpha-synuclein pathology. Depression and anxiety affect up to 40-50% of patients. Cognitive impairment ranges from mild cognitive impairment (PD-MCI) to frank PD dementia. Autonomic dysfunction manifests as orthostatic hypotension, urinary urgency, and erectile dysfunction. Pain, both central neuropathic and peripheral, is common. Fatigue is one of the most disabling non-motor symptoms reported by patients.

## Initial Pharmacotherapy

| Drug Class | Examples | Key Advantages | Key Disadvantages |
|---|---|---|---|
| Levodopa | Carbidopa-levodopa | Most effective motor control | Motor complications (wearing off, dyskinesia) |
| Dopamine agonists | Pramipexole, ropinirole, rotigotine | Lower dyskinesia risk | Impulse control disorders (17%), somnolence, edema |
| MAO-B inhibitors | Rasagiline, selegiline, safinamide | Mild benefit, possible disease modification | Mild efficacy as monotherapy |
| NMDA antagonist | Amantadine | Tremor, later for dyskinesia | Livedo reticularis, hallucinations, edema |
| Anticholinergics | Trihexyphenidyl, benztropine | Tremor in young patients | Cognitive impairment in elderly (avoid) |

### Levodopa

Levodopa is the most effective symptomatic therapy for PD motor symptoms. It is always combined with a peripheral decarboxylase inhibitor (carbidopa or benserazide) to prevent peripheral conversion to dopamine. The typical starting dose is carbidopa-levodopa 25/100 mg three times daily, titrated to effect. Motor complications including wearing off and dyskinesia develop over time, but these are related to disease duration and disease severity rather than to the duration of levodopa exposure itself. The PD-MED and LEAP trials support the early use of levodopa.

### Dopamine Agonists

Non-ergot dopamine agonists include pramipexole, ropinirole, and rotigotine (a transdermal patch). They carry a lower risk of dyskinesia compared to levodopa but are less effective for motor symptom control. Important side effects include impulse control disorders (pathological gambling, hypersexuality, compulsive shopping, binge eating) occurring in approximately 17% of patients, excessive daytime somnolence, peripheral edema, and hallucinations. They have traditionally been preferred in younger patients under 60 to delay dyskinesia, though this approach is increasingly questioned.

### MAO-B Inhibitors

Rasagiline, selegiline, and safinamide provide mild symptomatic benefit as monotherapy or as adjuncts. The ADAGIO trial suggested a possible disease-modifying effect of rasagiline at 1 mg, though this has not been replicated. They are generally well-tolerated; combining with SSRIs carries a theoretical serotonin syndrome risk that is clinically rare.

### Other Agents

Amantadine, an NMDA antagonist, is useful for tremor and later in the disease course for dyskinesia management. Anticholinergics (trihexyphenidyl, benztropine) are used primarily for tremor in young patients but should be avoided in the elderly due to cognitive side effects.

<image>Flowchart showing initial treatment algorithm for newly diagnosed Parkinson disease based on age, symptom severity, and functional impairment</image>

## The Levodopa Controversy

The historical concern that levodopa accelerates neurodegeneration is not supported by evidence. The LEAP trial, using a delayed-start design, found no difference in outcomes between early and delayed levodopa initiation, arguing against both disease modification and toxicity. The current consensus is that levodopa should be started when symptoms cause functional impairment, and there is no benefit to delaying treatment.

## Clinical Pearls

Always examine for asymmetry: PD remains asymmetric throughout its course, and symmetric parkinsonism should raise suspicion for atypical parkinsonian syndromes. Screen for impulse control disorders at every visit in patients on dopamine agonists using the QUIP questionnaire. The combination of anosmia, RBD, and constipation indicates high prodromal PD risk, warranting consideration of DaTscan and alpha-synuclein SAA. If a patient does not respond to adequate levodopa doses (at least 600 mg/day for a reasonable trial), the diagnosis should be reconsidered. Cogwheel rigidity alone, without bradykinesia, is not sufficient for a PD diagnosis. The levodopa equivalent daily dose (LEDD) calculation is essential for comparing regimens and managing motor complications.

<image>Braak staging diagram showing the caudal-to-rostral progression of alpha-synuclein pathology from the medulla and olfactory bulb to the neocortex</image>

## References
- Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601.
- Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized delayed-start trial of levodopa in Parkinson's disease (LEAP). N Engl J Med. 2019;380(4):315-324.
- PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease. Lancet. 2014;384(9949):1196-1205.
- Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178-190.
- Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-595.